Skip to main content

Advertisement

Table 4 Mean change in central systolic blood pressure (mmHg) after EMPA therapy separated according to median of different variables

From: How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Variable Age HbA1c Copeptin Heart rate LDL-cholesterol Uric acid Systolic BP hsCRP
≥ median − 6.23 ± 11.2 − 6.46 ± 11.1 − 8.94 ± 10.2 − 4.49 ± 9.89 − 5.50 ± 12.1 − 6.21 ± 9.54 − 5.13 ± 10.6 − 4.21 ± 10.3
< median − 3.76 ± 9.83 − 3.61 ± 9.97 − 1.78 ± 9.83 − 5.48 ± 11.3 − 4.51 ± 9.06 − 3.76 ± 11.45 − 4.88 ± 10.7 − 5.77 ± 10.9
p-value 0.378 0.308 0.009 0.724 0.724 0.378 0.928 0.576
  1. Data are given as mean ± SD
  2. hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24 h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood pressure